Iwanaga K - Search Results

1

Pharmacokinetic assessment of absorptive interaction of oral etoposide and morphine in rats.

Miyazaki M, Nishimura C, Minamida M, Iwanaga K, Kakemi M. Miyazaki M, et al. Among authors: iwanaga k. Biol Pharm Bull. 2014;37(3):371-7. doi: 10.1248/bpb.b13-00716. Epub 2013 Dec 17. Biol Pharm Bull. 2014. PMID: 24351551 Free article.

2

Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs.

Iwanaga K, Kushibiki T, Miyazaki M, Kakemi M. Iwanaga K, et al. Biol Pharm Bull. 2006 Mar;29(3):508-12. doi: 10.1248/bpb.29.508. Biol Pharm Bull. 2006. PMID: 16508155 Free article.

3

Inhibitory effects of furanocoumarin derivatives in Kampo extract medicines on P-glycoprotein at the blood-brain barrier.

Iwanaga K, Yoneda S, Hamahata Y, Miyazaki M, Shibano M, Taniguchi M, Baba K, Kakemi M. Iwanaga K, et al. Biol Pharm Bull. 2011;34(8):1246-51. doi: 10.1248/bpb.34.1246. Biol Pharm Bull. 2011. PMID: 21804213 Free article.

4

Pharmacokinetics and toxicity of repeated oral etoposide is altered by morphine coadministration in rats.

Miyazaki M, Kawase T, Nishimura C, Kitamura T, Iwanaga K, Kakemi M. Miyazaki M, et al. Among authors: iwanaga k. Eur J Drug Metab Pharmacokinet. 2015 Sep;40(3):335-41. doi: 10.1007/s13318-014-0212-y. Epub 2014 Jun 27. Eur J Drug Metab Pharmacokinet. 2015. PMID: 24969687

5

Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.

Miyazaki M, Sawada S, Nishide T, Iwanaga K, Morimoto K, Kakemi M. Miyazaki M, et al. Among authors: iwanaga k. Biol Pharm Bull. 2000 Jan;23(1):87-96. doi: 10.1248/bpb.23.87. Biol Pharm Bull. 2000. PMID: 10706418 Free article.

6

Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.

Miyazaki M, Maekawa C, Iwanaga K, Morimoto K, Kakemi M. Miyazaki M, et al. Among authors: iwanaga k. Biol Pharm Bull. 2000 Nov;23(11):1363-9. doi: 10.1248/bpb.23.1363. Biol Pharm Bull. 2000. PMID: 11085367 Free article.

7

Characterization of organogel as a novel oral controlled release formulation for lipophilic compounds.

Iwanaga K, Sumizawa T, Miyazaki M, Kakemi M. Iwanaga K, et al. Int J Pharm. 2010 Mar 30;388(1-2):123-8. doi: 10.1016/j.ijpharm.2009.12.045. Epub 2010 Jan 4. Int J Pharm. 2010. PMID: 20045041

8

Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.

Iwanaga K, Hayashi M, Hamahata Y, Miyazaki M, Shibano M, Taniguchi M, Baba K, Kakemi M. Iwanaga K, et al. Drug Metab Dispos. 2010 Aug;38(8):1286-94. doi: 10.1124/dmd.110.032847. Epub 2010 May 12. Drug Metab Dispos. 2010. PMID: 20463004

9

Chronopharmacological assessment identified GLUT4 as a factor responsible for the circadian variation of the hypoglycemic effect of tolbutamide in rats.

Miyazaki M, Fujii T, Takeda N, Magotani H, Iwanaga K, Kakemi M. Miyazaki M, et al. Among authors: iwanaga k. Drug Metab Pharmacokinet. 2011;26(5):503-15. doi: 10.2133/dmpk.dmpk-11-rg-021. Epub 2011 Jun 28. Drug Metab Pharmacokinet. 2011. PMID: 21712613 Free article.

10

Enhancing the intestinal absorption of poorly water-soluble weak-acidic compound by controlling local pH.

Iwanaga K, Kato S, Miyazaki M, Kakemi M. Iwanaga K, et al. Drug Dev Ind Pharm. 2013 Dec;39(12):1887-94. doi: 10.3109/03639045.2012.668911. Epub 2012 Mar 26. Drug Dev Ind Pharm. 2013. PMID: 22443480

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

375 results

Search Page

Filters